Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Aaron T. Gerds, MDMS, Tetsuzo Tauchi, MD, Ellen K. Ritchie, MD, Michael W. Deininger, MD PhD, Catriona HM Jamieson, MD PhD, Ruben Mesa, MD FACP, Mark Lawrence Heaney, MD PhD, Norio Komatsu, MD PhD, Hironobu Minami, MD PhD, M. Naveed Shaik, PhD, Xiaoxi Zhang, PhD, Christine DiRienzo, PhD, Mirjana Zeremski, MD, Geoffrey Chan, MD, Moshe Talpaz, MD

Blood (2017) 130 (Supplement 1): 258.

https://doi.org/10.1182/blood.V130.Suppl_1.258.258

Published: 2017

Journal Articles

Tracking Normal and Chronic Myeloid Leukemia Progenitor Cell Cycle Kinetics in a Defined Niche Using Live Time Lapse Confocal Imaging with Fucci2BL a Novel Lentiviral Bicistronic Reporter

Gabriel Pineda, PhD, Kathleen M Lennon, BS, Nathaniel P Delos-Santos, BS, Florence Lambert-Fliszar, Gennarina L Riso, BS, Marco A Marra, PhD, Sheldon Morris, MD, Asako Sakaue-Sawano, PhD, Atsushi Miyawaki, PhD, Catriona HM Jamieson, MD PhD

Blood (2015) 126 (23): 1863.

https://doi.org/10.1182/blood.V126.23.1863.1863

Published: 2015

Journal Articles

Inflammatory Cytokine-Responsive ADAR1 Impairs Let-7 Biogenesis and Promotes Leukemia Stem Cell Generation

Maria Anna Zipeto, PhD, Angela Court Recart, Nathaniel Delos Santos, Qingfei Jiang, PhD, Leslie A Crews, PhD, Catriona HM Jamieson, MD PhD

Blood (2015) 126 (23): 4014.

https://doi.org/10.1182/blood.V126.23.4014.4014

Published: 2015

Journal Articles

Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts

Michael Y. Choi, MD, George F. Widhopf, II, PhD, Januario Castro, MD, Hongying Li, PhD, Reilly L Kidwell, BS, BA, CCRC, Sam C Zhang, B.A., Tiffany Juarez, PhD, Susette Gorak, Laura Z. Rassenti, PhD, Karen Messer, PhD, Charles Prussak, PhD, Catriona HM Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2015) 126 (23): 1736.

https://doi.org/10.1182/blood.V126.23.1736.1736

Published: 2015

Journal Articles

Regulation of Self-Renewal through Modulation of Let-7 Stem Cell Regulatory Family of microRNAs in Chronic Myeloid Leukemia Stem Cells

Maria Anna Zipeto, PhD, Qingfei Jiang, PhD, Leslie A Crews, PhD, Angela Court Recart, Catriona HM Jamieson, MD PhD

Blood (2014) 124 (21): 4527.

https://doi.org/10.1182/blood.V124.21.4527.4527

Published: 2014

Journal Articles

Tracking Human Myeloma Cell Therapeutic Resistance Using a Novel Diagnostic Assay for Detection of RNA Editing Biomarkers of Cancer Stem Cell Generation

Elisa Lazzari, MS, Leslie A Crews, PhD, Maria Anna Zipeto, PhD, Shawn Ali, BA, Catriona HM Jamieson, MD PhD

Blood (2014) 124 (21): 3406.

https://doi.org/10.1182/blood.V124.21.3406.3406

Published: 2014

Journal Articles

The Role Of CD44 Isoform Expression In Niche Resident Chronic Myeloid Leukemia Stem Cell Evolution

Cayla Mason, BSc, Frida Holm, PhD, Eva Hellqvist, PhD, Christian Barrett, PhD, Kelly A Frazer, Ph.D., Anil Sadarangani, PhD, Catriona HM Jamieson, MD, PhD

Blood (2013) 122 (21): 4028.

https://doi.org/10.1182/blood.V122.21.4028.4028

Published: 2013

Journal Articles

Long-Term Follow Up Of a Randomized Phase II Study Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Catriona HM Jamieson, MD, PhD, Nashat Y Gabrail, MD MRCP, Claudia Lebedinsky, MD, Guozhi Gao, PhD, Moshe Talpaz, MD

Blood (2013) 122 (21): 4047.

https://doi.org/10.1182/blood.V122.21.4047.4047

Published: 2013

Journal Articles

Inhibition Of Inflammation Driven Leukemia Stem Cell Self-Renewal With a Selective JAK2 Antagonist

Angela C Court Recart, BS, MS, Anil Sadarangani, PhD, Elizabeth Chun, MSc, Cayla N Mason, BS, Qingfei Jiang, PhD, Christian L Barrett, Ph.D., Russell Wall, BS, Daniel J Goff, PhD, Ifat Geron, MSc, Alice Shih, Heather S. Leu, B.S., Wenxue Ma, M.D., Ph.D., Mark D. Minden, MD PhD, Kelly A Frazer, Ph.D., Marco A. Marra, PhD, Leslie A Crews, PhD, Catriona HM Jamieson, MD, PhD

Blood (2013) 122 (21): 1481.

https://doi.org/10.1182/blood.V122.21.1481.1481

Published: 2013

Journal Articles

Targeting Of Chronic Lymphocytic Leukemia B Cells With a Humanized Monoclonal Antibody Specific For ROR1

George F. Widhopf, II, PhD, Bing Cui, Ph.D., Christina C.N. Wu, PhD, Jian Yu, PhD, Fitzgerald Lao, Rommel Tawatao, Rongrong Wu, Esther Avery, B.S., Anil Sadarangani, PhD, Charles Prussak, PhD, Catriona HM Jamieson, MD, PhD, Dennis A. Carson, M.D., Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 2873.

https://doi.org/10.1182/blood.V122.21.2873.2873

Published: 2013

Journal Articles

Cirmtuzumab Vedotin (UC-961ADC3), An Anti-ROR1-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment For ROR1-Positive Leukemia and Solid Tumors

Bing Cui, Ph.D, George F. Widhopf, II, PhD, Charles E. Prussak, Ph.D., Christina C.N. Wu, PhD, Anil Sadarangani, PhD, Suping Zhang, PhD, Fitzgerald Lao, Catriona HM Jamieson, MD, PhD, Dennis A. Carson, M.D, Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 1637.

https://doi.org/10.1182/blood.V122.21.1637.1637

Published: 2013

Journal Articles

Treatment With Hedgehog Inhibitor, PF-04449913, Attenuates Leukemia-Initiation Potential In Acute Myeloid Leukemia Cells

Nobuaki Fukushima, MD, Yosuke Minami, MD, PhD, Fumihiko Hayakawa, MD, PhD, Hitoshi Kiyoi, MD, PhD, Anil Sadarangani, PhD, Catriona HM Jamieson, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2013) 122 (21): 1649.

https://doi.org/10.1182/blood.V122.21.1649.1649

Published: 2013

Journal Articles

A Highly Selective SF3B1-Targeted Splicing Inhibitor Reduces Human CD34+ Cell Survival and Self-Renewal In Acute Myeloid Leukemia

Larissa Balaian, Ph.D., Leslie A Crews, PhD, Marianna Zipeto, Kulidjian Anna, MD, Edward D. Ball, M.D., Michael D Burkart, PhD, Catriona HM Jamieson, MD, PhD

Blood (2013) 122 (21): 1653.

https://doi.org/10.1182/blood.V122.21.1653.1653

Published: 2013

Journal Articles

Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis

Catriona HM Jamieson, MD, PhD, Robert P Hasserjian, MD, Jason Gotlib, MD, MS, Jorge E. Cortes, MD, Richard M. Stone, MD, Moshe Talpaz, MD, Jürgen Thiele, MD, PhD, Scott J Rodig, MD, PhD, Abhay Patki, PhD MBA, Kaida Wu, PhD, MD, Jingyang Wu, MSc, Olga Pozdnyakova, MD, PhD

Blood (2013) 122 (21): 2823.

https://doi.org/10.1182/blood.V122.21.2823.2823

Published: 2013

NARROW

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Tracking Normal and Chronic Myeloid Leukemia Progenitor Cell Cycle Kinetics in a Defined Niche Using Live Time Lapse Confocal Imaging with Fucci2BL a Novel Lentiviral Bicistronic Reporter

Inflammatory Cytokine-Responsive ADAR1 Impairs Let-7 Biogenesis and Promotes Leukemia Stem Cell Generation

Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts

Regulation of Self-Renewal through Modulation of Let-7 Stem Cell Regulatory Family of microRNAs in Chronic Myeloid Leukemia Stem Cells

Tracking Human Myeloma Cell Therapeutic Resistance Using a Novel Diagnostic Assay for Detection of RNA Editing Biomarkers of Cancer Stem Cell Generation

The Role Of CD44 Isoform Expression In Niche Resident Chronic Myeloid Leukemia Stem Cell Evolution

Long-Term Follow Up Of a Randomized Phase II Study Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

Inhibition Of Inflammation Driven Leukemia Stem Cell Self-Renewal With a Selective JAK2 Antagonist

Targeting Of Chronic Lymphocytic Leukemia B Cells With a Humanized Monoclonal Antibody Specific For ROR1

Cirmtuzumab Vedotin (UC-961ADC3), An Anti-ROR1-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment For ROR1-Positive Leukemia and Solid Tumors

Treatment With Hedgehog Inhibitor, PF-04449913, Attenuates Leukemia-Initiation Potential In Acute Myeloid Leukemia Cells

A Highly Selective SF3B1-Targeted Splicing Inhibitor Reduces Human CD34+ Cell Survival and Self-Renewal In Acute Myeloid Leukemia

Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only